Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Swain

Showing results (441-450 of 532) with videos related to

Pageof 54
Sort By:
ESMO Open|May 1, 2022
Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancerN D Modi, N O Danell, R N A Perry, et al.
Journal of Virology|February 28, 2006
Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virusDanher Wang, Nicholas U Raja, Charles M Trubey, et al.
The Plant Cell|March 4, 2008
Potential sites of bioactive gibberellin production during reproductive growth in ArabidopsisJianhong Hu, Melissa G Mitchum, Neel Barnaby, et al.
The Lancet. Oncology|March 16, 2020
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 studySandra M Swain, David Miles, Sung-Bae Kim, et al.
Breast Cancer Research and Treatment|January 11, 2016
Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclinesAna Barac, Filipa Lynce, Karen L Smith, et al.
Cancer Treatment Reviews|April 17, 2022
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and managementSandra M Swain, Mizuki Nishino, Lisa H Lancaster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2017
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety studyS M Swain, M S Ewer, G Viale, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 7, 2021
Post-cricoid and Upper Oesophagus Cancers Treated with Organ Preservation Using Intensity-modulated Image-guided Radiotherapy: a Phase II Prospective Study of Outcomes, Toxicity and Quality of LifeS G Laskar, S Sinha, M Singh, et al.
Cancer|June 17, 2014
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancerPeter A Kaufman, Kenneth J Bloom, Howard Burris, et al.
Clinical and Translational Science|February 8, 2025
A Randomized Hybrid-Effectiveness Trial Comparing Pharmacogenomics (PGx) to Standard Care: The PGx Applied to Chronic Pain Treatment in Primary Care (PGx-ACT) TrialD Max Smith, Rut Beyene, Paul Kolm, et al.
Pageof 54

Showing results (441-450 of 532) with videos related to

Sort By:
Pageof 54
ESMO Open|May 1, 2022
Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancerN D Modi, N O Danell, R N A Perry, et al.
Journal of Virology|February 28, 2006
Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virusDanher Wang, Nicholas U Raja, Charles M Trubey, et al.
The Plant Cell|March 4, 2008
Potential sites of bioactive gibberellin production during reproductive growth in ArabidopsisJianhong Hu, Melissa G Mitchum, Neel Barnaby, et al.
The Lancet. Oncology|March 16, 2020
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 studySandra M Swain, David Miles, Sung-Bae Kim, et al.
Breast Cancer Research and Treatment|January 11, 2016
Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclinesAna Barac, Filipa Lynce, Karen L Smith, et al.
Cancer Treatment Reviews|April 17, 2022
Multidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis-Focus on proactive monitoring, diagnosis, and managementSandra M Swain, Mizuki Nishino, Lisa H Lancaster, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 19, 2017
Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety studyS M Swain, M S Ewer, G Viale, et al.
Clinical Oncology (Royal College of Radiologists (Great Britain))|December 7, 2021
Post-cricoid and Upper Oesophagus Cancers Treated with Organ Preservation Using Intensity-modulated Image-guided Radiotherapy: a Phase II Prospective Study of Outcomes, Toxicity and Quality of LifeS G Laskar, S Sinha, M Singh, et al.
Cancer|June 17, 2014
Assessing the discordance rate between local and central HER2 testing in women with locally determined HER2-negative breast cancerPeter A Kaufman, Kenneth J Bloom, Howard Burris, et al.
Clinical and Translational Science|February 8, 2025
A Randomized Hybrid-Effectiveness Trial Comparing Pharmacogenomics (PGx) to Standard Care: The PGx Applied to Chronic Pain Treatment in Primary Care (PGx-ACT) TrialD Max Smith, Rut Beyene, Paul Kolm, et al.
Pageof 54